Boston Scientific initiates global study to assess Emblem™ subcutaneous implantable defibrillator (S-ICD) in primary prevention patients with low ejection fraction

Global Study from Boston Scientific into EMBLEM™ S-ICD

A global study from Boston Scientific (NYSE: BSX) has been initiated to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for primary prevention of sudden cardiac death in the setting of severely reduced cardiac function (left ventricular ejection fraction ≤ 35 percent). Primary prevention patients do not have a previously documented life-threatening arrhythmic event, but are at risk of sudden cardiac death and thereby indicated to receive an implantable defibrillator. This group of patients represents the highest proportion of patients that are implanted with transvenous ICD (TV-ICDs) devices today in the United States (U.S.) and European Union (EU).

The global study from Boston Scientific to further demonstrate the usefulness of the S-ICD System in this particular patient population, the UNTOUCHED study will compare outcomes during an18-month follow-up period to objective performance criteria derived from the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) study. The landmark MADIT-RIT study evaluated shock rates in 1,500 patients implanted with TV-ICD devices and is one of the largest randomized trials to assess shock reduction strategies for TV-ICD devices.[i]

“The MADIT-RIT trial demonstrated that standardized programming using higher rate cutoffs and longer delays to therapy reduces the incidence of inappropriate shocks for TV-ICDs,” said Dr. Lucas Boersma, EU principal investigator and electrophysiologist at St. Antonius Hospital, The Netherlands. “The UNTOUCHED trial will examine the incidence of all-cause shocks when using the EMBLEM S-ICD System with standardized therapy settings similar to MADIT-RIT.”

Boston Scientific EMBLEM S-ICD in place
Boston Scientific EMBLEM S-ICD in place

The first patient enrolled in the global, multi-site, prospective, non-randomized study received an EMBLEM

S-ICD System implant by Dr. Craig Barr, cardiologist at Russells Hall Hospital in Dudley, England. The study will enroll a minimum of 2,015 patients at up to 200 sites worldwide. Enrollments in the U.S. will begin later this summer.

“In the published data to date, we have observed S-ICD devices demonstrate comparable inappropriate shock rates for arrhythmias to TV-ICDs,” said Michael Gold, M.D., Ph.D., U.S. principal investigator and chief of cardiology and the Michael E. Assey professor of medicine at Medical University of South Carolina, Charleston. “Ideally, this trial will demonstrate S-ICD devices can either meet or improve upon the inappropriate shock rates experiences with TV-ICDs in MADIT-RIT within this large patient population.”

The EMBLEM S-ICD System – the next generation of the Boston Scientific S-ICD System – received CE Mark earlier this year, was approved by the Food & Drug Administration (FDA) in March of 2015, launched in Europe starting in May, and became commercially available in the U.S. earlier this month in preparation for a planned full U.S. launch during the third quarter of 2015.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information,